Summary:
In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss conjugation and bioconjugation approaches to make ASOs and small molecules more tolerable while improving targeting. Technologies discussed include ADCs, PDCs, SMDCs, VDCs, RDCs and AOCs. Specifically they address:
- Biological and chemical challenges for these therapies
- Building out scalable manufacturing and a regulatory strategy
- Hurdles to overcome to get products to market
To learn more about the PODD Conference, please visit Drug-Delivery.org.
Moderators
Sudhakar Garad, PhD
Global Head of Chemical and Pharmaceutical Profiling
Novartis
Panelists
Mandana Borna, PhD
Head of Oligonucleotide Drug Product Development
Biogen
Suman Luthra, PhD
Director | Discovery Pharmaceutical Sciences
Merck
Stefan Yohe, PhD
Associate Research Fellow
Pfizer
Benjamin Smith, PhD
Senior Director, Protein Science and Bioconjugation
Voyager Therapeutics
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.